<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical features of varicella-zoster virus infection: Chickenpox</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical features of varicella-zoster virus infection: Chickenpox</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical features of varicella-zoster virus infection: Chickenpox</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mary A Albrecht, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection and is distributed worldwide. VZV infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). Primary VZV infection results in the diffuse vesicular rash of varicella, or chickenpox. Endogenous reactivation of latent VZV typically results in a localized skin infection known as herpes zoster, or shingles.</p><p>Primary varicella infection in children is generally a mild disease compared to more severe presentations in adults or immunocompromised patients of any age. The rates of infection, hospitalizations, and mortality have all declined in the US since the introduction of the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> in 1995; immunization is recommended in all children before the age of five years and in nonimmune adults. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a> and  <a class="medical medical_review" href="/d/html/8304.html" rel="external">"Epidemiology of varicella-zoster virus infection: Chickenpox"</a>.)</p><p>The major clinical manifestations and complications of chickenpox will be reviewed here. Infection in the neonate and the treatment and prevention of this infection, including the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a>, and herpes zoster are discussed separately. (See  <a class="medical medical_review" href="/d/html/4969.html" rel="external">"Varicella-zoster infection in the newborn"</a> and  <a class="medical medical_review" href="/d/html/8336.html" rel="external">"Treatment of varicella (chickenpox) infection"</a> and  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)"</a> and  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults"</a> and  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster"</a> and  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TRANSMISSION AND VIROLOGY</span><span class="headingEndMark"> — </span>Chickenpox is highly contagious, with secondary household attack rates of &gt;90 percent in susceptible individuals [<a href="#rid1">1,2</a>].</p><p>Infection control issues within hospitals are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Transmission routes</span><span class="headingEndMark"> — </span>Transmission occurs in susceptible hosts via contact with aerosolized droplets from nasopharyngeal secretions of an infected individual or by direct cutaneous contact with vesicle fluid from skin lesions [<a href="#rid1">1</a>]. Airborne transmission of VZV to susceptible nursing staff has also been reported in a hospital unit [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Viremia</span><span class="headingEndMark"> — </span>VZV is a double-stranded, linear DNA virus encoding approximately 75 proteins [<a href="#rid1">1,4,5</a>] and possessing a lipid-containing envelope with glycoprotein spikes. After gaining entry, the virus undergoes localized replication at an undefined site with concurrent replication in regional lymph nodes by days four to six [<a href="#rid6">6</a>]. This is followed by a primary viremic phase with seeding of the reticuloendothelial system. A secondary phase of viremia occurs after approximately nine days [<a href="#rid7">7</a>] and persists through the development of skin lesions [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Incubation period</span><span class="headingEndMark"> — </span>The average incubation period for varicella infection is 14 to 16 days, although this interval can range from 10 to 21 days [<a href="#rid10">10</a>]. The period of infectivity is generally considered to last from 48 hours prior to the onset of rash until skin lesions have fully crusted.</p><p>Administration of <a class="drug drug_general" data-topicid="9442" href="/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a> (VZIG) following exposure can prolong the incubation period from 21 days to 28 days. (See  <a class="medical medical_review" href="/d/html/4047.html" rel="external">"Prevention and control of varicella-zoster virus in hospitals"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Reinfection</span><span class="headingEndMark"> — </span>It has been generally thought that second episodes of varicella infection in immunocompetent individuals rarely occur [<a href="#rid11">11,12</a>], although subclinical reinfection with VZV is common [<a href="#rid13">13</a>]. However, post-vaccine surveillance programs have suggested that a second episode of primary varicella in immunocompetent individuals might be more common than previously thought [<a href="#rid14">14</a>]. More than 95 percent of first infections were physician diagnosed, epidemiologically linked to another case, or had a rash consistent with varicella; the same was true for reported second infections. The study demonstrated the following results:</p><p class="bulletIndent1"><span class="glyph">●</span>While the overall incidence of primary varicella declined substantially after the introduction of vaccine (2934 versus 587 cases in 1995 and 1999, respectively), the proportion of cases of varicella in individuals with a previous history of the disease increased from 4.5 to 13.3 percent. None of the patients with a second episode of varicella had been vaccinated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>People who reported reinfections were generally healthy. There was a family history of repeat infections in 45 percent of people who reported reinfections.</p><p></p><p>Of note, diagnoses made within this study were clinically-based and not laboratory-confirmed.</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Primary infection with VZV routinely occurs during childhood and is usually a benign self-limited illness in immunocompetent children. However, varicella can be a severe disease in adolescents, adults, and immunosuppressed or immunocompromised individuals of any age. Secondary cases in household contacts appear to be more severe than primary cases [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Uncomplicated varicella</span><span class="headingEndMark"> — </span>The clinical manifestations of varicella in healthy children generally develop within fifteen days after the exposure and typically include a prodrome of fever, malaise, or pharyngitis, loss of appetite [<a href="#rid1">1</a>], followed by the development of a generalized vesicular rash, usually within 24 hours.</p><p>The vesicular rash of varicella, which is usually pruritic, appears in successive crops over several days. The lesions begin as macules that rapidly become papules followed by characteristic vesicles; these lesions can then develop a pustular component followed by the formation of crusted papules [<a href="#rid10">10</a>] (<a class="graphic graphic_picture graphicRef55533" href="/d/graphic/55533.html" rel="external">picture 1</a>). The patient with varicella typically has lesions in different stages of development on the face, trunk and extremities. New vesicle formation generally stops within four days, and most lesions have fully crusted by day six in normal hosts [<a href="#rid1">1</a>]. Crusts tend to fall off within about one to two weeks and leave a temporary area of hypopigmentation in the skin [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Impact of vaccine on clinical manifestations</span><span class="headingEndMark"> — </span>Approximately 20 percent of children who receive one dose of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> may develop varicella infection, known as "breakthrough disease", if exposed to VZV [<a href="#rid15">15,16</a>]. A report on the clinical and epidemiological characteristics of varicella in populations with increasing vaccine coverage between 1997 and 2005 identified the following trends [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In vaccinated children 1 to 14 years of age, varicella was more often mild and modified than in unvaccinated children (eg, less fever and a lower number of lesions).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The accompanying rash was significantly more likely to be atypical in nature among vaccinated children (eg, maculopapular).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complications were less likely to be reported among vaccinated children than unvaccinated children.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic complications (eg, encephalitis) continue to be rare [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">COMPLICATIONS OF VARICELLA</span><span class="headingEndMark"> — </span>Prior to the introduction of <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> in 1995, healthy children and adolescents accounted for 80 percent of the estimated 9300 annual varicella-related hospitalizations in the United States [<a href="#rid2">2,18</a>].</p><p>A survey was conducted from 1990 to 1992 of over 250,000 members of a health maintenance organization to assess the epidemiology of varicella and its complications [<a href="#rid19">19</a>]. Following a medical record review process, a total of 107 confirmed complications were identified, including bacterial skin infections and pneumonia. Skin infections were associated with the most hospitalizations in the youngest age group (&lt;15 years of age); pneumonia was associated with hospitalization in persons &gt;19 years of age. (See  <a class="medical medical_review" href="/d/html/8304.html" rel="external">"Epidemiology of varicella-zoster virus infection: Chickenpox"</a>.)</p><p>After the introduction of vaccine, the number of complications in children dramatically declined, although the most common complication has remained bacterial superinfections; in the Varicella Active Surveillance Project (VASP), complications included skin and soft tissue infections (42 percent), dehydration (11 percent), and neurologic complications (9 percent) [<a href="#rid17">17</a>].</p><p>Although vaccine attenuates disease manifestations substantially, complications can still occur and are discussed below [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Skin/soft tissue infections</span><span class="headingEndMark"> — </span>Primary varicella infection in children has been associated with an increased incidence of invasive group A streptococcal soft tissue infection [<a href="#rid20">20-23</a>]. Infectious complications have included cellulitis, myositis, necrotizing fasciitis, and toxic shock syndrome [<a href="#rid20">20-25</a>]. </p><p class="headingAnchor" id="H12"><span class="h2">Neurologic complications</span><span class="headingEndMark"> — </span>Encephalitis and, mostly in the past, Reye syndrome, are the most serious complications of VZV infection, although they are uncommonly seen [<a href="#rid17">17</a>]. Other less common neurologic complications include transient focal deficits, aseptic meningitis, transverse myelitis, vasculitis, and hemiplegia [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H13"><span class="h3">Encephalitis</span><span class="headingEndMark"> — </span>In one series of serious varicella-related complications, encephalitis accounted for 20 percent of varicella-related hospitalizations [<a href="#rid26">26</a>]. Two distinct forms of encephalitis have been described [<a href="#rid1">1,17,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute cerebellar ataxia</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse encephalitis</p><p></p><p>These disorders typically develop toward the end of the first week of the exanthem, but there are cases in which central nervous system involvement has preceded the rash [<a href="#rid27">27,28</a>].</p><p>Acute cerebellar ataxia most often develops in children, occurring in about 1 in 4000 varicella infections in children younger than 15 years of age [<a href="#rid29">29</a>]. It has a limited time course and is generally followed by complete recovery. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6206.html" rel="external">"Acute cerebellar ataxia in children"</a>.)</p><p>Diffuse encephalitis most often occurs in adults, but young children are also at increased risk [<a href="#rid30">30,31</a>]. The clinical manifestations include delirium, seizures, and focal neurologic signs. Pathologic examination has revealed three main patterns; although one usually predominates, mixed features are seen in many cases [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A medium to large vessel vasculopathy with bland or hemorrhagic infarctions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A small vessel vasculopathy with mixed ischemic and demyelinating lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A ventriculitis or periventriculitis</p><p></p><p>Reported mortality rates approach 10 percent and long-term neurologic sequelae reported in up to 15 percent of survivors [<a href="#rid30">30,31,33</a>]. Not surprisingly, varicella encephalitis is more severe in immunosuppressed hosts, such as patients with AIDS and transplant recipients. Such patients typically have a fulminant course with seizures, mental status changes, and focal deficits including stroke syndromes.</p><p>There is no proven effective therapy once encephalitis occurs. <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">Acyclovir</a> has been used with anecdotal success [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Reye syndrome</span><span class="headingEndMark"> — </span>Reye syndrome, an illness developing during the course of varicella infection in children, typically presents with a distinct constellation of symptoms including nausea, vomiting, headache, excitability, delirium, and combativeness with frequent progression to coma [<a href="#rid36">36</a>]. Since salicylate use was identified as a major precipitating factor for the development of Reye syndrome [<a href="#rid37">37</a>], this complication has virtually disappeared, concomitant with advisories against using salicylates in febrile children. In a surveillance study from 1980 through 1997, 1207 cases were reported; the number of cases peaked in 1980 at 555 and dramatically declined, with warnings issued against the use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in patients with varicella or influenza [<a href="#rid38">38</a>]. From 1987 to 1993 fewer than 36 cases per year were reported; fewer than two cases per year were noted from 1994 to 1997. (See  <a class="medical medical_review" href="/d/html/6154.html" rel="external">"Acute toxic-metabolic encephalopathy in children", section on 'Reye syndrome'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>In immunocompetent children with varicella, pneumonia remains an uncommon complication; in contrast, pneumonia accounts for the majority of morbidity and mortality seen in adults with varicella, although it is infrequently seen since the introduction of vaccine (eg, 60 per 10,000 cases) [<a href="#rid17">17</a>].</p><p>In immunocompetent adults, varicella pneumonia has a reported incidence of about one in 400 cases [<a href="#rid29">29,39,40</a>] and carries an overall mortality of between 10 and 30 percent [<a href="#rid41">41,42</a>]. However, in patients with respiratory failure who require mechanical ventilation, mortality rates approach 50 percent despite institution of aggressive therapy and appropriate supportive measures [<a href="#rid43">43-45</a>].</p><p>Risk factors linked to the development of varicella pneumonia include cigarette smoking [<a href="#rid33">33,41,46</a>], pregnancy [<a href="#rid47">47</a>], immunosuppression [<a href="#rid31">31</a>], and male sex [<a href="#rid39">39</a>]. Pregnancy may be an additional risk factor for severe varicella pneumonia although the incidence of pneumonia does not appear to be higher in pregnant patients with varicella [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/8331.html" rel="external">"Varicella-zoster virus infection in pregnancy"</a>.)</p><p>Varicella pneumonia typically develops insidiously within one to six days after the rash has appeared with symptoms of progressive tachypnea, dyspnea, and dry cough; hemoptysis has occasionally been reported [<a href="#rid42">42</a>]. Patients demonstrate impaired gas exchange with progressive hypoxemia. Chest radiographs typically reveal diffuse bilateral infiltrates; in the early stages a nodular component may be present, which can subsequently become calcified [<a href="#rid42">42,49,50</a>]. Prompt administration of intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> has been associated with clinical improvement and resolution of pneumonia in selected series [<a href="#rid42">42,44,51</a>]. (See  <a class="medical medical_review" href="/d/html/8332.html" rel="external">"Acyclovir: An overview"</a>.)</p><p>The use of steroids as adjunctive therapy for the treatment of life-threatening varicella pneumonia is controversial and has not been well studied. An uncontrolled study evaluated 15 adult patients with varicella pneumonia; 11 of these 15 patients (73 percent) were smokers and eight (53 percent) required mechanical ventilation [<a href="#rid45">45</a>]. All were treated with intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> and supportive measures; six also received steroids. The patients who received steroids had a shorter hospitalization (median difference of 10 days) and a shorter ICU stay (median difference eight days). The authors of this report suggested a randomized trial, which to date has not been performed.</p><p class="headingAnchor" id="H16"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Biopsy proven visceral hepatic involvement with varicella is uncommon, but when it occurs, generally affects immunosuppressed hosts including transplant recipients and AIDS patients; the outcome is frequently fatal [<a href="#rid52">52-55</a>]. Clinical varicella hepatitis in healthy individuals is rare despite the fact that asymptomatic or subclinical transaminase elevation, coincident with the onset of varicella, has been documented in 77 percent of children in one series [<a href="#rid56">56</a>].</p><p>In immunosuppressed hosts with varicella hepatitis, the most common presenting features have typically included cutaneous vesicular lesions, fever, and acute abdominal or back pain [<a href="#rid55">55,57</a>]. However, the rash may precede [<a href="#rid54">54</a>], appear coincident with [<a href="#rid52">52</a>], or follow [<a href="#rid53">53</a>] the onset of hepatitis, which can delay the diagnosis of this complication. The development of varicella hepatitis with widespread visceral dissemination has been reported in a bone marrow transplant patient in the absence of a rash [<a href="#rid58">58</a>]. Fulminant liver failure with disseminated intravascular coagulation (DIC) and gastrointestinal hemorrhage with dissemination have also been reported [<a href="#rid59">59,60</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other clinical manifestations among children and adults have included diarrhea, pharyngitis, and otitis media [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H18"><span class="h1">IMMUNOSUPPRESSED HOSTS</span><span class="headingEndMark"> — </span>Patients with a history of underlying malignancy, steroid use or immunosuppressive therapy, HIV infection, or solid organ transplantation are susceptible for disseminated varicella due to impaired cellular immunity. Immunosuppressed hosts who develop varicella experience more frequent severe morbidity and higher mortality rates compared to normal hosts. While only 0.1 percent of varicella infections develop in this population, this group accounted for as many as 25 percent of varicella-related deaths in the prevaccine era [<a href="#rid1">1</a>].</p><p>Patients with rheumatologic diseases treated with tumor necrosis factor (TNF) antagonists remain at selectively increased risk for more severe primary varicella infections compared with the general population [<a href="#rid61">61</a>]. A retrospective review utilizing a hospital database and national patient registry of rheumatologic diseases, conducted in Spain, evaluated hospitalizations due to chickenpox in patients with rheumatic diseases. In rheumatologic patients exposed to TNF antagonists, the estimated incidence rate of hospitalization due to chickenpox was 26 cases per 100,000 (95% CI 10-69) compared with the expected rate of 1.9 (95% CI 1.8-2.0) in the general population.</p><p>Clinical manifestations in the immunosuppressed host can include ongoing development of crops of vesicles over weeks, large and hemorrhagic skin lesions, pneumonia, or widespread disease with disseminated intravascular coagulation [<a href="#rid10">10</a>].</p><p><a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">Varicella vaccine</a> programs appear to have had a positive impact on severe varicella infection in this patient subset. Surveillance mortality data compiled from the National Center for Health Statistics during the period from 1990-2001 [<a href="#rid62">62</a>] reviewed mortality rates in high-risk individuals for which varicella was identified as the underlying cause of death. High-risk individuals were defined as those with conditions for which vaccination is contraindicated: cancer, HIV infection or AIDS, and other immunodeficiencies:</p><p class="bulletIndent1"><span class="glyph">●</span>Between 1990 and 2001, cancer accounted for the greatest proportion of high-risk conditions among those younger than 20 years (71 percent) and those of 50 years of age or older (90 percent). Among high-risk persons 20 to 49 years of age, HIV infection or AIDS were the most common conditions (58 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall, however, patients with high-risk conditions accounted for few of the varicella deaths in this study (approximately 20 percent).</p><p></p><p>The authors surmised that patients who were identified to be at high risk for severe varicella may have received early aggressive therapy with intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> that favorably impacted survival. A higher rate of varicella vaccination among close contacts of persons ineligible for vaccination may also have occurred; thus herd immunity may have prevented some cases of primary infection [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/8332.html" rel="external">"Acyclovir: An overview"</a>.)</p><p>There are few data on varicella in HIV-infected children. One natural history in 57 HIV-infected children included patients with primary varicella or HIV-infected controls without a history of varicella (matched by age and CD4 count) [<a href="#rid63">63</a>]. Thirty children developed varicella, but only one case was judged to be severe; 22 of 30 had received <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> therapy.</p><p>While the outcome of primary infection was favorable in this population of HIV-infected children, the incidence of later herpes zoster infection was high. Of the children with a history of varicella, eight (27 percent) developed herpes zoster an average of 1.9 years after the episode of primary varicella [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H3148068269"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110219.html" rel="external">"Society guideline links: Varicella-zoster virus"</a>.)</p><p class="headingAnchor" id="H22144419"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15375.html" rel="external">"Patient education: Chickenpox (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/3997.html" rel="external">"Patient education: Chickenpox prevention and treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virology</strong> – Varicella-zoster virus (VZV) is one of eight herpesviruses known to cause human infection and is distributed worldwide. VZV infection causes two clinically distinct forms of disease: varicella (chickenpox) and herpes zoster (shingles). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> – Chickenpox is highly contagious, with secondary household attack rates of &gt;90 percent in susceptible individuals. Transmission occurs in susceptible hosts via contact with aerosolized droplets from nasopharyngeal secretions of an infected individual or by direct cutaneous contact with vesicle fluid from skin lesions. (See <a class="local">'Transmission and virology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Primary varicella infection in children is generally a mild disease compared to more severe presentations in adults or immunocompromised patients of any age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uncomplicated varicella</strong> – The clinical manifestations of varicella generally develop within fifteen days after the exposure and typically include a prodrome of fever, malaise, or pharyngitis, followed by the development of a generalized vesicular rash. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complications</strong> – Complications of varicella in children can include bacterial superinfection while pneumonia is more common in adults. (See <a class="local">'Complications of varicella'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disseminated varicella</strong> – Patients with a history of underlying malignancy, steroid use or immunosuppressive therapy, HIV infection, or solid organ transplantation are susceptible for disseminated varicella due to impaired cellular immunity. (See <a class="local">'Immunosuppressed hosts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of vaccination</strong> – The incidences of infection, hospitalizations, and mortality have all declined since the introduction of the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> in 1995. Varicella vaccination is discussed separately. (See  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Straus SE, Ostrove JM, Inchauspé G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221.</a></li><li><a class="nounderline abstract_t">Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 1996; 10:571.</a></li><li><a class="nounderline abstract_t">Leclair JM, Zaia JA, Levin MJ, et al. Airborne transmission of chickenpox in a hospital. N Engl J Med 1980; 302:450.</a></li><li><a class="nounderline abstract_t">Dumas AM, Geelen JL, Mares W, Van Der Noordaa J. Infectivity and molecular weight of varicella-zoster virus DNA. J Gen Virol 1980; 47:233.</a></li><li><a class="nounderline abstract_t">Harper DR, Gilbert RL, Jeffries DJ. Molecular biology of varicella-zoster virus. A review prepared for the UK Advisory Group on Chickenpox. J Infect 1998; 36 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med 1999; 130:922.</a></li><li><a class="nounderline abstract_t">Lin TY, Huang YC, Ning HC, Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J 1997; 16:1162.</a></li><li><a class="nounderline abstract_t">Grose C. Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics 1981; 68:735.</a></li><li><a class="nounderline abstract_t">Ozaki T, Ichikawa T, Matsui Y, et al. Viremic phase in nonimmunocompromised children with varicella. J Pediatr 1984; 104:85.</a></li><li><a class="nounderline abstract_t">Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365.</a></li><li><a class="nounderline abstract_t">Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis 1984; 149:137.</a></li><li><a class="nounderline abstract_t">Junker AK, Angus E, Thomas EE. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatr Infect Dis J 1991; 10:569.</a></li><li><a class="nounderline abstract_t">Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 1983; 148:200.</a></li><li><a class="nounderline abstract_t">Hall S, Maupin T, Seward J, et al. Second varicella infections: are they more common than previously thought? Pediatrics 2002; 109:1068.</a></li><li><a class="nounderline abstract_t">Chaves SS, Zhang J, Civen R, et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J Infect Dis 2008; 197 Suppl 2:S127.</a></li><li><a class="nounderline abstract_t">Weinmann S, Chun C, Mullooly JP, et al. Laboratory diagnosis and characteristics of breakthrough varicella in children. J Infect Dis 2008; 197 Suppl 2:S132.</a></li><li><a class="nounderline abstract_t">Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis 2008; 197 Suppl 2:S94.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Recommended childhood immunization schedule--United States, January-June 1996. MMWR Morb Mortal Wkly Rep 1996; 44:940.</a></li><li><a class="nounderline abstract_t">Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995; 172:706.</a></li><li><a class="nounderline abstract_t">Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl 1:S91.</a></li><li><a class="nounderline abstract_t">Laupland KB, Davies HD, Low DE, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 2000; 105:E60.</a></li><li><a class="nounderline abstract_t">de Benedictis FM, Osimani P. Necrotising fasciitis complicating varicella. Arch Dis Child 2008; 93:619.</a></li><li><a class="nounderline abstract_t">Shirley R, Mackey S, Meagher P. Necrotising fasciitis: a sequelae of varicella zoster infection. J Plast Reconstr Aesthet Surg 2011; 64:123.</a></li><li><a class="nounderline abstract_t">Vugia DJ, Peterson CL, Meyers HB, et al. Invasive group A streptococcal infections in children with varicella in Southern California. Pediatr Infect Dis J 1996; 15:146.</a></li><li><a class="nounderline abstract_t">Zurawski CA, Bardsley M, Beall B, et al. Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis 1998; 27:150.</a></li><li><a class="nounderline abstract_t">Johnson R, Milbourn PE. Central nervous system manifestations of chickenpox. Can Med Assoc J 1970; 102:831.</a></li><li><a class="nounderline abstract_t">Dangond F, Engle E, Yessayan L, Sawyer MH. Pre-eruptive varicella cerebellitis confirmed by PCR. Pediatr Neurol 1993; 9:491.</a></li><li><a class="nounderline abstract_t">Häusler M, Schaade L, Kemény S, et al. Encephalitis related to primary varicella-zoster virus infection in immunocompetent children. J Neurol Sci 2002; 195:111.</a></li><li><a class="nounderline abstract_t">Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78:723.</a></li><li><a class="nounderline abstract_t">Preblud SR. Age-specific risks of varicella complications. Pediatrics 1981; 68:14.</a></li><li><a class="nounderline abstract_t">Fleisher G, Henry W, McSorley M, et al. Life-threatening complications of varicella. Am J Dis Child 1981; 135:896.</a></li><li><a class="nounderline abstract_t">Kleinschmidt-DeMasters BK, Amlie-Lefond C, Gilden DH. The patterns of varicella zoster virus encephalitis. Hum Pathol 1996; 27:927.</a></li><li><a class="nounderline abstract_t">Fairley CK, Miller E. Varicella-zoster virus epidemiology--a changing scene? J Infect Dis 1996; 174 Suppl 3:S314.</a></li><li><a class="nounderline abstract_t">Poscher ME. Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review. AIDS 1994; 8:1115.</a></li><li><a class="nounderline abstract_t">Cinque P, Bossolasco S, Vago L, et al. Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? Clin Infect Dis 1997; 25:634.</a></li><li><a class="nounderline abstract_t">Hurwitz ES, Nelson DB, Davis C, et al. National surveillance for Reye syndrome: a five-year review. Pediatrics 1982; 70:895.</a></li><li><a class="nounderline abstract_t">Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. N Engl J Med 1985; 313:849.</a></li><li><a class="nounderline abstract_t">Belay ED, Bresee JS, Holman RC, et al. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med 1999; 340:1377.</a></li><li><a class="nounderline abstract_t">WEBER DM, PELLECCHIA JA. VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN. JAMA 1965; 192:572.</a></li><li><a class="nounderline abstract_t">Hockberger RS, Rothstein RJ. Varicella pneumonia in adults: a spectrum of disease. Ann Emerg Med 1986; 15:931.</a></li><li><a class="nounderline abstract_t">Triebwasser JH, Harris RE, Bryant RE, Rhoades ER. Varicella pneumonia in adults. Report of seven cases and a review of literature. Medicine (Baltimore) 1967; 46:409.</a></li><li><a class="nounderline abstract_t">Schlossberg D, Littman M. Varicella pneumonia. Arch Intern Med 1988; 148:1630.</a></li><li><a class="nounderline abstract_t">Feldman S. Varicella-zoster virus pneumonitis. Chest 1994; 106:22S.</a></li><li><a class="nounderline abstract_t">Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 1990; 12:788.</a></li><li><a class="nounderline abstract_t">Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 1998; 114:426.</a></li><li><a class="nounderline abstract_t">Ellis ME, Neal KR, Webb AK. Is smoking a risk factor for pneumonia in adults with chickenpox? Br Med J (Clin Res Ed) 1987; 294:1002.</a></li><li><a class="nounderline abstract_t">Esmonde TF, Herdman G, Anderson G. Chickenpox pneumonia: an association with pregnancy. Thorax 1989; 44:812.</a></li><li><a class="nounderline abstract_t">HARRIS RE, RHOADES ER. VARICELLA PNEUMONIA COMPLICATING PREGNANCY. REPORT OF A CASE AND REVIEW OF LITERATURE. Obstet Gynecol 1965; 25:734.</a></li><li><a class="nounderline abstract_t">Floudas CS, Kanakis MA, Andreopoulos A, Vaiopoulos GA. Nodular lung calcifications following varicella zoster virus pneumonia. QJM 2008; 101:159.</a></li><li><a class="nounderline abstract_t">Varicella death of an unvaccinated, previously healthy adolescent — Ohio, 2009. MMWR Morb Mortal Wkly Rep 2013; 62:261.</a></li><li><a class="nounderline abstract_t">Wilkins EG, Leen CL, McKendrick MW, Carrington D. Management of chickenpox in the adult. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect 1998; 36 Suppl 1:49.</a></li><li><a class="nounderline abstract_t">Feldhoff CM, Balfour HH Jr, Simmons RL, et al. Varicella in children with renal transplants. J Pediatr 1981; 98:25.</a></li><li><a class="nounderline abstract_t">Patti ME, Selvaggi KJ, Kroboth FJ. Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med 1990; 88:77.</a></li><li><a class="nounderline abstract_t">Soriano V, Bru F, González-Lahoz J. Fatal varicella hepatitis in a patient with AIDS. J Infect 1992; 25:107.</a></li><li><a class="nounderline abstract_t">Kusne S, Pappo O, Manez R, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995; 60:619.</a></li><li><a class="nounderline abstract_t">Pitel PA, McCormick KL, Fitzgerald E, Orson JM. Subclinical hepatic changes in varicella infection. Pediatrics 1980; 65:631.</a></li><li><a class="nounderline abstract_t">Dits H, Frans E, Wilmer A, et al. Varicella-zoster virus infection associated with acute liver failure. Clin Infect Dis 1998; 27:209.</a></li><li><a class="nounderline abstract_t">Rogers SY, Irving W, Harris A, Russell NH. Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant 1995; 15:805.</a></li><li><a class="nounderline abstract_t">Anderson DR, Schwartz J, Hunter NJ, et al. Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch Intern Med 1994; 154:2101.</a></li><li><a class="nounderline abstract_t">Sherman RA, Silva J Jr, Gandour-Edwards R. Fatal varicella in an adult: case report and review of the gastrointestinal complications of chickenpox. Rev Infect Dis 1991; 13:424.</a></li><li><a class="nounderline abstract_t">García-Doval I, Pérez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69:1751.</a></li><li><a class="nounderline abstract_t">Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450.</a></li><li><a class="nounderline abstract_t">Gershon AA, Mervish N, LaRussa P, et al. Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection. J Infect Dis 1997; 176:1496.</a></li></ol></div><div id="topicVersionRevision">Topic 8284 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829675" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856352" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The epidemiology of varicella-zoster virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7351951" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Airborne transmission of chickenpox in a hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infectivity and molecular weight of varicella-zoster virus DNA</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9514102" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Molecular biology of varicella-zoster virus. A review prepared for the UK Advisory Group on Chickenpox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10375341" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recent advances in varicella-zoster virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427463" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral acyclovir prophylaxis of varicella after intimate contact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6273782" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Variation on a theme by Fenner: the pathogenesis of chickenpox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6317835" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Viremic phase in nonimmunocompromised children with varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17046469" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6321605" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical reinfection with varicella-zoster virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1891288" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recurrent varicella-zoster virus infections in apparently immunocompetent children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6310001" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunologic evidence of reinfection with varicella-zoster virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042544" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Second varicella infections: are they more common than previously thought?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419385" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419386" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Laboratory diagnosis and characteristics of breakthrough varicella in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419417" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Varicella among adults: data from an active surveillance project, 1995-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531913" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Recommended childhood immunization schedule--United States, January-June 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658062" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The epidemiology of varicella and its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353193" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Varicella-zoster virus: atypical presentations and unusual complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10799624" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18567772" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Necrotising fasciitis complicating varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570582" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Necrotising fasciitis: a sequelae of varicella zoster infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8822288" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Invasive group A streptococcal infections in children with varicella in Southern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9675469" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5445045" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Central nervous system manifestations of chickenpox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7605561" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pre-eruptive varicella cerebellitis confirmed by PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897240" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Encephalitis related to primary varicella-zoster virus infection in immunocompetent children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3763290" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Population-based studies of varicella complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7243498" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Age-specific risks of varicella complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7293988" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Life-threatening complications of varicella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816888" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The patterns of varicella zoster virus encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896538" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Varicella-zoster virus epidemiology--a changing scene?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986408" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Successful treatment of varicella zoster virus meningoencephalitis in patients with AIDS: report of four cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314452" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7145544" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : National surveillance for Reye syndrome: a five-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4033715" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Public Health Service study on Reye's syndrome and medications. Report of the pilot phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228187" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reye's syndrome in the United States from 1981 through 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14284857" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : VARICELLA PNEUMONIA: STUDY OF PREVALENCE IN ADULT MEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3740580" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Varicella pneumonia in adults: a spectrum of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4864340" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Varicella pneumonia in adults. Report of seven cases and a review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3382308" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Varicella pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8020329" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Varicella-zoster virus pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2237118" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9726725" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Corticosteroids in life-threatening varicella pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3119001" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Is smoking a risk factor for pneumonia in adults with chickenpox?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2688179" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chickenpox pneumonia: an association with pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14289538" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : VARICELLA PNEUMONIA COMPLICATING PREGNANCY. REPORT OF A CASE AND REVIEW OF LITERATURE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178592" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nodular lung calcifications following varicella zoster virus pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Varicella death of an unvaccinated, previously healthy adolescent—Ohio, 2009</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9514108" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Management of chickenpox in the adult. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7005416" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Varicella in children with renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403757" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Varicella hepatitis in the immunocompromised adult: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522315" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fatal varicella hepatitis in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7570963" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7360555" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Subclinical hepatic changes in varicella infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9675478" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Varicella-zoster virus infection associated with acute liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7670413" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092915" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1866547" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fatal varicella in an adult: case report and review of the gastrointestinal complications of chickenpox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20551153" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689583" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Decline in mortality due to varicella after implementation of varicella vaccination in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9395360" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Varicella-zoster virus infection in children with underlying human immunodeficiency virus infection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
